Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects

NCT ID: NCT04762355

Last Updated: 2021-02-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-30
• Study Completion Date: 2019-01-03

Brief Summary

Dry eye disease (DED) is a keratoconjunctive disorder that "is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. The goal of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple ascending doses of palovarotene ophthalmic solution in healthy adult subjects.

Conditions

Dry Eye Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Dose 1

Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen

Group Type: EXPERIMENTAL

Palovarotene

Intervention Type: DRUG

ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3

Vehicle

Intervention Type: DRUG

Placebo-to-match palovarotene ophthalmic solution vials

Dose 2

Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen

Group Type: EXPERIMENTAL

Palovarotene

Intervention Type: DRUG

ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3

Vehicle

Intervention Type: DRUG

Placebo-to-match palovarotene ophthalmic solution vials

Dose 3

Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen

Group Type: EXPERIMENTAL

Palovarotene

Intervention Type: DRUG

ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3

Vehicle

Intervention Type: DRUG

Placebo-to-match palovarotene ophthalmic solution vials

Interventions

Palovarotene

ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3

Intervention Type: DRUG

Vehicle

Placebo-to-match palovarotene ophthalmic solution vials

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy, adult, male or female, 18 to 55 years of age, inclusive, at screening.
• Continuous non-smoker who had not used nicotine containing products for at least 3 months prior to the first dosing and throughout the study, based on subject self-reporting.
• Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 at screening.
• Medically healthy as deemed by the Investigator or delegate and determined by medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory results obtained within 28 days before the start of the study.
• Tolerate topical administration to the eye.
• Best corrected visual acuity is equal or better than 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in both eyes.

Exclusion Criteria

• Mentally or legally incapacitated or had significant emotional problems at the time of the screening visit or expected during the conduct of the study.
• History or presence of clinically significant medical (systemic or ophthalmic) or psychiatric condition or disease in the opinion of the Investigator or delegate.
• History of any illness that, in the opinion of the Investigator or delegate, might have confounded the results of the study or posed an additional risk to the subject by their participation in the study.
• History or presence of alcoholism or drug abuse within the past 18 months prior to the first dosing.
• History or presence of hypersensitivity or idiosyncratic reaction to the study drug, systemic retinoids such as isotretinoin or related compounds (e.g., topical tretinoins, vitamin A), fluorescein, or parabens or to the inactive ingredients in the study formulation.
• History of any ocular surgery or laser within the past 6 months prior to screening.
• History of herpes simplex keratitis.
• History or presence of:

1. Any chronic eye disease other than refractive error, incipient cataract, strabismic amblyopia, or anisometropic amblyopia.

2. Acute eye disease (such as infection, corneal abrasion, or allergy) within the past 6 months from screening.

• Any currently active ocular condition that required use of topical eye drops.
• Had an intraocular pressure >21 mmHg.
• If ophthalmological examination at screening or Day 1 predose revealed abnormalities of the cornea, evidence of ocular infection, inflammation (dry eyes, blepharitis, allergic conjunctivitis, iritis, and uveitis), advanced or moderately injected pterygium, keratitis, narrow anterior chamber angles, clinically significant Meibomian gland dysfunction, or any finding in either the anterior segment or posterior segment of the eye, that could have compromised the study as per Investigator or delegate discretion.
• Any macular integrity issues or optic nerve head (ONH) cupping/abnormality on retinal exam.
• Occurrence of active seasonal allergies including ocular allergies (e.g., annual hay fever).
• Needed to wear contact lenses during the study.
• Positive results at screening for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus.
• Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing and throughout the study, unless permitted by the Investigator or delegate.
• Any drugs known to be significant inhibitors and inducers of CYP3A4 enzymes, including St. John's Wort, for 30 days prior to the first dosing and throughout the study.
• Ocular medication of any kind (including artificial tears), antihistamines, anticholinergics, and/or oral/nasal steroids for 30 days prior to the first dosing and throughout the study.
• Isotretinoin or other systemic retinoids beginning 30 days or 5 half-lives, whichever was longer

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ipsen

INDUSTRY

Sponsor Role: collaborator

Clementia Pharmaceuticals Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ipsen Medical Director

Role: STUDY_DIRECTOR

Ipsen

Locations

Algorithme Pharma facility

Québec, , Canada

Countries

Canada

Other Identifiers

PVO-3A-101

Identifier Type: -

Identifier Source: org_study_id